Mursla Bio Joins European Consortium to Advance Extracellular Vesicle Research and Clinical Translation
Mursla Bio, a leader in extracellular vesicle (EV) science, has been invited to join the EVEREST consortium, a leading European initiative aimed at advancing EV research, innovation, and clinical translation for the benefit of patients.
As part of the 22-institution consortium, Mursla Bio will provide oversight on the 'scaling and commercialization' work package for EV products, particularly focusing on clinical diagnostics. The company will also host researchers from institutions across Europe and send staff members on secondments to other partners.
Mursla Bio's dynamic biopsy technology combines the accuracy of tissue biopsies with the ease of liquid biopsy sample collection, providing a non-invasive intervention that offers comprehensive biological insights. This is made possible by advanced EV science and an innovative extracellular omics approach supported by Mursla Bio's technologies, including organ-specific EV isolation from biofluids for precise targeting and an AI-enabled multi-omics workflow for disease biomarker identification.
"We are pleased to have been selected to join the EVEREST consortium as an industry partner," said Pierre Arsène, Founder and CEO of Mursla Bio. "Our cross-Atlantic expertise will guide the consortium in scaling up and commercializing clinically relevant products. Together, we aim to shape the best of EV research into highly innovative clinical tests that will benefit millions of patients over the next decade."
The EVEREST project is coordinated by the University College Dublin and received funding from the European Union's Horizon Europe research and innovation program under grant agreement No 101183034. The consortium aims to facilitate the translation of scientific discoveries into clinical insights, leveraging academic and industry collaborations.
As the field of EVs continues to progress rapidly, initiatives like EVEREST are essential in driving the advancement of EV science towards practical applications that can improve patient outcomes. With Mursla Bio's expertise at the forefront, the scientific exchange within the program is expected to greatly benefit the field, allowing for innovative clinical products to emerge in the next decade.
Mursla Bio's inclusion in the EVEREST consortium marks a significant milestone in its mission to significantly improve cancer outcomes for at-risk patients through dynamic biopsy technology.